--- title: "Inspire Medical Systems, Inc. (INSP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation" description: "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Inspire Medical Systems, Inc. (INSP) following a significant stock drop of 40.6% after the company reported Q2 ear" type: "news" locale: "en" url: "https://longbridge.com/en/news/252384514.md" published_at: "2025-08-10T15:00:02.000Z" --- # Inspire Medical Systems, Inc. (INSP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation > Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Inspire Medical Systems, Inc. (INSP) following a significant stock drop of 40.6% after the company reported Q2 earnings and lowered its revenue guidance. The investigation focuses on delays in the rollout of the "Inspire V" system due to billing issues with Medicare. Investors are encouraged to assist the investigation by contacting the firm. NEW YORK CITY, NY / ACCESS Newswire / August 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inspire Medical Systems, Inc. ("Inspire" or "the Company") . Investors who purchased Inspire securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/INSP. **Investigation Details** On August 4, 2025, Inspire reported Q2 earnings, lowering its full-year revenue guidance and disclosing delays in the rollout of its "Inspire V" system. The Company revealed that treatment centers had postponed the adoption of its new system due to not being able to bill Medicare until July 1, 2025. Following this news, Inspire stock dropped almost 40.6% in intraday trading on August 5, 2025. **What's Next?** If you are aware of any facts relating to this investigation or purchased Inspire securities, you can assist this investigation by visiting the firm's site: bgandg.com/INSP. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660 **There is No Cost to You** We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. **Why Bronstein, Gewirtz & Grossman** Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. **Contact** Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com **SOURCE:** Bronstein, Gewirtz & Grossman, LLC View the original press release on ACCESS Newswire ### Related Stocks - [INSP.US - Inspire Medical](https://longbridge.com/en/quote/INSP.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 启迪医疗｜8-K：2025 财年 Q4 营收 2.69 亿美元超过预期 | | [Link](https://longbridge.com/en/news/275661624.md) | | 启迪医疗｜8-K：2025 财年 Q4 营收 2.69 亿美元超过预期 | | [Link](https://longbridge.com/en/news/272324607.md) | | 启迪医疗系统第四季度的收入超过了预期 | 启迪医疗系统报告第四季度收入增长 12%，达到 2.691 亿美元，超出分析师预期。第四季度调整后每股收益为 1.65 美元。公司回购了 5000 万美元的股票，并将 2026 年的收入展望修订为 9.5 亿至 10 亿美元，预计调整后的营 | [Link](https://longbridge.com/en/news/275657598.md) | | 14:30 ETInspirien 宣布与 Coverys 进行战略合作，以加强其医疗事故项目 | Inspirien 宣布与 Coverys 达成战略合作，以增强其医疗事故保险项目。此次合作旨在扩大 Inspirien 在医疗责任市场的产品供应，通过 A.M. Best "A" 级承保公司提供保险。该合作将 Inspirien 在承保和 | [Link](https://longbridge.com/en/news/275650161.md) | | 19 位分析师对启迪医疗系统的评级意见是什么 | 启迪医疗系统（NYSE:INSP）在过去三个月内收到了 19 位分析师的评级，显示出看涨和看跌情绪的混合。12 个月的平均目标价为 124.11 美元，较之前的 127.35 美元有所下降。近期的行动包括几位分析师下调了他们的评级和目标价， | [Link](https://longbridge.com/en/news/275760186.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.